m.Stock by Mirae AssetOpen Demat Account
Swara Baby Products (FirstCry) IPO: Issue Date, Price, Lot Size and Everything You Need to Know

Swara Baby Products (FirstCry) IPO: Issue Date, Price, Lot Size and Everything You Need to Know

Swara Baby Products is a specialised manufacturer of disposable hygiene products, with operations spanning baby diapers, adult incontinence products and feminine hygiene. The company began as a captive manufacturing platform within the FirstCry ecosystem and has evolved into a broader contract-manufacturing business serving multiple brands and customers, while also developing its own brands. Its competitive position is built around manufacturing scale, product development, customer relationships and the ability to produce across multiple hygiene categories.

The IPO comes after three years of revenue growth but uneven profitability. Revenue from operations increased from ₹749.96 crore in FY24 to ₹942.97 crore in FY25 and ₹1,163.90 crore in FY26. PAT, however, declined from ₹93.97 crore to ₹80.67 crore before recovering to ₹95.59 crore. The proposed fresh capital is directed towards a new manufacturing project, debt reduction and investments in subsidiaries, while the OFS provides partial monetisation to existing shareholders.

Business model: contract manufacturing at scale

Swara Baby manufactures disposable hygiene products for customers under contract. Its portfolio includes baby diapers, adult diapers and feminine hygiene products such as sanitary napkins. The company also sells products under its own Cuddles and Shields brands.

The company is therefore not a pure consumer brand. A substantial part of its economic proposition comes from manufacturing for other brands and retailers. This model can reduce the need for large consumer-marketing expenditure while allowing the manufacturer to benefit from customers' distribution networks.  The controlling parent company of Swara Baby Products is Brainbees Solutions.

The trade-off is bargaining power. Contract manufacturers typically depend on customer volumes, product specifications, pricing negotiations and capacity utilisation. Large customers can provide scale and recurring demand, but they can also influence margins and shift production to alternative suppliers.

According to the TKC industry report cited in the DRHP, Swara Baby was India's largest contract manufacturer of disposable hygiene products by value in FY25. The company also reported market shares of approximately 37% in contract manufacturing of baby nappies and 36% in contract manufacturing of adult nappies in India.

Product portfolio: diversification beyond baby diapers

Baby diapers remain the historical foundation of the business, but the company has expanded into adult incontinence and feminine hygiene. This broadens the addressable market and reduces dependence on a single demographic category.

The adult incontinence opportunity is structurally different from baby diapers. Demand is influenced by ageing, healthcare requirements and long-term care, while baby diapers are linked more closely to birth rates, household income, urbanisation and product penetration. Feminine hygiene provides another consumption category with different usage patterns.

The strategic value of this diversification is that the same manufacturing capabilities—absorbent materials, non-woven fabrics, elastic components, converting equipment, quality systems and packaging—can be adapted across product categories. The economic benefit depends on maintaining high utilisation while avoiding excessive complexity in the manufacturing network.

Manufacturing footprint: concentrated but scalable

The company manufactures its products at four facilities in Madhya Pradesh. The concentration of manufacturing in one state creates a cluster advantage in terms of management, procurement and logistics, but it also creates geographic concentration risk.

The DRHP identifies risks from disruption to infrastructure, natural disasters, industrial accidents, workforce disruption, local regulations and other regional events. A significant disruption at one or more facilities could therefore affect production and customer supply.

The proposed IPO includes a substantial capital-expenditure programme for a new manufacturing project at Pithampur, Madhya Pradesh. The project is intended to increase capacity and support future growth. The success of the investment will depend on commissioning on schedule, customer demand and utilisation after completion.

Financial performance: steady revenue growth, uneven profit growth

Revenue from operations increased from ₹749.96 crore in FY24 to ₹942.97 crore in FY25 and ₹1,163.90 crore in FY26. This represents a two-year CAGR of approximately 24.6%.

Profitability has been less linear. PAT declined from ₹93.97 crore in FY24 to ₹80.67 crore in FY25 before increasing to ₹95.59 crore in FY26. EBITDA increased from ₹153.59 crore to ₹162.72 crore and then ₹192.77 crore over the same period.

₹ crore, unless stated

FY24

FY25

FY26

Revenue from operations

749.96

942.97

1,163.90

EBITDA

153.59

162.72

192.77

PAT

93.97

80.67

95.59

Net worth

319.36

399.92

553.22

Borrowings

260.08

354.82

443.06

EBITDA margin

20.48%

17.25%

16.56%

PAT margin

12.53%

8.55%

8.21%

ROE / RoNW

29.4%

22.7%

17.28%

Debt / equity

0.81x

0.89x

0.80x

Raw-material economics: a major margin determinant

Disposable hygiene products use significant quantities of absorbent pulp, super-absorbent polymers, non-woven fabrics, polyethylene films, elastics, adhesives and other materials. Changes in input prices can therefore affect gross margins materially.

Contract manufacturing provides some protection because large customers may negotiate pricing based on product specifications and input costs, but pass-through is not necessarily immediate or complete. A manufacturer can therefore experience a margin squeeze when raw-material inflation rises faster than customer price revisions.

The company's ability to procure at scale, optimise material consumption and reduce wastage is consequently as important as headline revenue growth. Manufacturing efficiency can create durable competitive advantage in a product category where price and quality are both closely scrutinised.

Capacity utilisation: the economic test for the next phase

The planned Pithampur project represents a major capital-allocation decision. Capacity expansion can support customer wins and reduce production bottlenecks, but it also raises depreciation, maintenance and fixed operating costs.

For a contract manufacturer, new capacity is economically attractive only when it can be filled with profitable orders. The key indicators will therefore be utilisation, revenue per manufacturing line, contribution margins and the time taken for new capacity to reach mature utilisation.

The company operates multiple facilities in Madhya Pradesh, giving it a manufacturing cluster. The new project could deepen that advantage if procurement, labour, engineering and logistics benefits scale with the larger footprint.

Customer concentration: scale can create dependence

Customer concentration is a significant risk disclosed by the company. The top ten customers accounted for more than 80% of revenue according to the DRHP's risk disclosures. This is understandable for a contract manufacturer because large customers can account for significant production volumes, but it also means the loss or reduction of one major relationship can affect capacity utilisation and financial performance.

The company's association with Brainbees Solutions, the parent of FirstCry, is strategically important. Brainbees currently owns 76.59% of Swara Baby, and Swara's origins are closely linked to FirstCry's effort to develop its own diaper supply chain.

The relationship also creates related-party and concentration considerations. The company states that transactions with Brainbees are conducted on an arm's-length basis. Post IPO, Brainbees is expected to remain the majority shareholder, while partially monetising its investment through the OFS.

FirstCry relationship: strategic support and governance consideration

Brainbees Solutions invested approximately ₹90.62 crore in Swara Baby in 2020 and subsequently increased its holding to 76.59%. Swara therefore remains strategically connected to the FirstCry ecosystem even after the proposed IPO.

The relationship can provide customer access, scale and commercial credibility. At the same time, investors should distinguish between strategic association and guaranteed future demand. The durability of the business should increasingly be assessed through the company's broader external customer base and the economics of third-party contracts.

The IPO also provides partial liquidity to the existing shareholder while allowing Swara Baby to raise fresh capital independently. This creates a dual objective: funding the company's manufacturing expansion and enabling the parent to monetise part of its investment.

International opportunity: exports can diversify demand

Swara has expanded beyond the domestic market and supplies products to international customers. Exports can diversify the customer base and provide access to markets where disposable hygiene penetration is still developing.

However, international business adds currency, logistics, regulatory, quality-certification and customer-credit considerations. The sustainability of export growth will depend on whether Swara can remain cost-competitive against manufacturers in other low-cost production centres.

Own brands: higher potential margin, higher commercial investment

Cuddles and Shields provide the company with its own brands in addition to contract manufacturing. Owning brands can potentially capture more of the consumer value chain and reduce dependence on manufacturing contracts.

The economics are different, however. Brand-led growth requires distribution, marketing, inventory investment and consumer acquisition. It also puts the company in direct competition with established hygiene brands and retailer-owned private labels.

For now, the contract-manufacturing business remains the core economic engine. The long-term strategic value of own brands will depend on whether they can scale without requiring disproportionate marketing expenditure.

Balance sheet: growth has been funded partly through debt

Borrowings increased from ₹260.08 crore in FY24 to ₹354.82 crore in FY25 and ₹443.06 crore in FY26. Net worth increased from ₹319.36 crore to ₹399.92 crore and then ₹553.22 crore. Debt-to-equity remained around 0.8x.

The absolute increase in borrowings reflects the capital requirements of a growing manufacturing business. The IPO proposes ₹100 crore for repayment or prepayment of certain borrowings, which should reduce finance-cost pressure and improve balance-sheet flexibility.

A further ₹27.5 crore is proposed to be invested in wholly owned subsidiaries—Solis Hygiene, Swara Hygiene and KAEHPL—for repayment or prepayment of their borrowings. The capital structure therefore remains an important part of the IPO rationale.

Use of IPO proceeds: capacity plus balance-sheet repair

The proposed fresh issue is up to ₹500 crore. Approximately ₹198.21 crore is earmarked for part-financing the capital expenditure of a new manufacturing project. Another ₹100 crore is intended for repayment or prepayment of specified borrowings of Swara Baby.

Approximately ₹27.5 crore is proposed to be invested in wholly owned subsidiaries for repayment or prepayment of their borrowings. The remaining amount is intended for unidentified acquisitions, strategic initiatives and general corporate purposes, subject to the terms disclosed in the DRHP.

The allocation shows a balanced capital strategy: the IPO is not solely a growth-capex transaction. A meaningful portion strengthens the balance sheet and reduces existing financial obligations.

The economics of contract manufacturing

Contract manufacturing can be attractive when a company combines scale, customer relationships and high asset utilisation. The manufacturer avoids the full cost of building consumer brands while still benefiting from large production volumes.

The downside is that customers can compare multiple manufacturers, negotiate pricing and shift volumes when capacity or economics change. This can make margins structurally lower than those of successful consumer brands.

Swara's market position as India's largest contract manufacturer by value in FY25 provides some scale advantage. The ability to maintain that position while improving margins and diversifying customers will be more important than simply increasing production capacity.

Key strengths

  • Largest contract manufacturer of disposable hygiene products in India by value in FY25, according to the TKC industry report cited in the DRHP.

  • Approximately 37% share in India's contract manufacturing of baby nappies and 36% in adult nappies, according to the DRHP's industry analysis.

  • Diversified exposure across baby hygiene, adult incontinence and feminine hygiene.

  • Manufacturing relationship with Brainbees/FirstCry provides scale and strategic ecosystem access.

  • Four manufacturing facilities in Madhya Pradesh provide a concentrated manufacturing base.

  • FY26 revenue of ₹1,163.90 crore and EBITDA of ₹192.77 crore.

  • Growing international and third-party customer exposure alongside FirstCry-linked business.

  • Proposed new manufacturing facility provides a defined capacity-expansion pathway.

  • Fresh capital also supports debt reduction, strengthening the balance sheet.

Key risks to monitor

  • Customer concentration: Top ten customers account for more than 80% of revenue.

  • Parent relationship: Brainbees remains the majority shareholder and a strategically important customer ecosystem.

  • Manufacturing concentration: All four current facilities are located in Madhya Pradesh.

  • Raw-material inflation: Absorbent materials, polymers, pulp, non-wovens and other inputs can pressure margins.

  • Margin compression: EBITDA margin declined from 20.48% in FY24 to 16.56% in FY26 despite strong revenue growth.

  • Leverage: Borrowings increased to ₹443.06 crore by FY26.

  • Capacity-utilisation risk: New manufacturing capacity may initially operate below optimal utilisation.

  • Contract-manufacturing economics: Large customers can exert pricing pressure and shift volumes.

  • Execution risk: Delays in the proposed Pithampur project could affect growth plans.

  • Regional disruption: Concentration of facilities in Madhya Pradesh exposes production to local infrastructure and workforce disruptions.

  • Own-brand risk: Cuddles and Shields require different commercial capabilities from contract manufacturing.

  • Acquisition risk: A portion of IPO proceeds may be used for unidentified acquisitions and strategic initiatives.

What to watch after the IPO

  • Capacity utilisation across existing and new manufacturing facilities

  • Revenue growth versus installed-capacity growth

  • EBITDA and PAT margins

  • Raw-material cost as a percentage of revenue

  • Customer concentration and contribution from non-FirstCry customers

  • Share of exports in revenue

  • Growth of adult incontinence and feminine hygiene products

  • Cuddles and Shields brand sales and marketing economics

  • Debt reduction after deployment of IPO proceeds

  • ROCE and return on incremental capital expenditure

  • Working-capital intensity and operating cash flow

  • Order visibility and contract renewal rates with major customers

The bigger picture

Swara Baby Products is best viewed as a scaled hygiene-product manufacturing platform rather than simply a baby-care company. Its evolution from a FirstCry-linked diaper manufacturing operation into a broader contract manufacturer across baby, adult and feminine hygiene has expanded its addressable market.

The financial record shows healthy revenue growth but more moderate earnings growth. Revenue increased by approximately 55% between FY24 and FY26, while PAT was only marginally higher than FY24. EBITDA margins also compressed during the period. This makes margin recovery and capital efficiency central to the next stage of the story.

The IPO provides two types of capital: growth capital for a new manufacturing project and balance-sheet capital through debt repayment. That should give the company greater capacity and financial flexibility. The challenge is ensuring that the additional capacity is filled with profitable customer demand rather than simply increasing the fixed-cost base.

The most important structural monitorable is customer diversification. A contract manufacturer can have significant scale and still remain vulnerable if a handful of customers account for most of its volumes. Swara's ability to broaden third-party and international relationships while maintaining its FirstCry-linked base will determine how independent and resilient the business becomes after listing.

More Related Articles

Stalwart People Services India IPO: Issue Date, Price, Lot Size and Everything You Need to Know

Stalwart People Services India IPO: Issue Date, Price, Lot Size and Everything You Need to Know

Calendar graphicNovember 20, 2026 | 0 mins read

Stalwart People Services India operates in the business-services space, providing security, surveillance, facility management and staffing solutions to institutional customers. Its offering combines traditional manned guarding with AI-enabled video surveillance, hard and soft facility management, and workforce solutions. The company has expanded rapidly across India and the Middle East, serving more than 1,000 clients across thousands of locations.

Read More
Pragyawan Technologies IPO: Scaling a Government-Led Solutions Platform

Pragyawan Technologies IPO: Scaling a Government-Led Solutions Platform

Calendar graphicNovember 20, 2026 | 0 mins read

Pragyawan Technologies operates across two broad verticals: Skill Development and Utility Solutions. Its model combines procurement, contract manufacturing, system integration, project execution and operations and maintenance to deliver specification-driven products and services to government departments, public-sector undertakings, educational institutions and other institutional customers.

Read More
Innoterra IPO: Date, Price, Lot Size and Everything You Need to Know

Innoterra IPO: Date, Price, Lot Size and Everything You Need to Know

Calendar graphicNovember 20, 2026 | 0 mins read

nnoterra is the Indian operating entity of the Switzerland-headquartered Innoterra Group. Its business spans three principal verticals: raw milk procurement and supply, cattle nutrition, and FarmLink, which covers fresh fruits and staples. The company describes its model as technology-led and asset-light. Technology is used to connect farmers with enterprise customers, capture quality and transaction data, coordinate fulfilment and improve traceability. Physical infrastructure is still essential, particularly in milk: the company operates bulk milk collection centres and bulk milk cooling units, while transportation, warehouses and certain other facilities can be operated through partners or third parties.

Read More
View All